X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (74) 74
index medicus (72) 72
stanford-v (67) 67
oncology (55) 55
chemotherapy (49) 49
hodgkin disease - drug therapy (48) 48
antineoplastic combined chemotherapy protocols - therapeutic use (47) 47
disease (44) 44
hematology (43) 43
female (40) 40
male (40) 40
adult (38) 38
abvd (36) 36
middle aged (35) 35
treatment outcome (34) 34
hodgkin disease - pathology (33) 33
neoplasm staging (32) 32
hodgkin disease - radiotherapy (27) 27
prognosis (27) 27
adolescent (26) 26
hodgkin disease - therapy (26) 26
hodgkin lymphoma (26) 26
radiotherapy (25) 25
combined modality therapy (24) 24
hodgkin's disease (24) 24
aged (22) 22
doxorubicin - administration & dosage (22) 22
involved-field radiotherapy (22) 22
positron-emission-tomography (22) 22
bleomycin - administration & dosage (21) 21
hodgkin disease - mortality (21) 21
lymphomas (21) 21
randomized-trial (20) 20
stem-cell transplantation (20) 20
antineoplastic combined chemotherapy protocols - administration & dosage (19) 19
vinblastine - administration & dosage (19) 19
combination chemotherapy (18) 18
antineoplastic combined chemotherapy protocols - adverse effects (17) 17
hodgkin disease - diagnosis (17) 17
brentuximab vedotin (16) 16
cancer (16) 16
disease-free survival (16) 16
care and treatment (15) 15
stage (15) 15
stanford v (15) 15
trial (15) 15
dacarbazine - administration & dosage (14) 14
doxorubicin - therapeutic use (14) 14
beacopp (13) 13
bleomycin (13) 13
bleomycin - therapeutic use (13) 13
radiation-therapy (13) 13
retrospective studies (13) 13
survival analysis (13) 13
vinblastine (13) 13
hematology, oncology and palliative medicine (12) 12
mopp/abv hybrid (12) 12
prognostic score (12) 12
vinblastine - therapeutic use (12) 12
vincristine - administration & dosage (12) 12
young adult (12) 12
hodgkin's lymphoma (11) 11
prednisone - administration & dosage (11) 11
risk factors (11) 11
etoposide - administration & dosage (10) 10
etoposide - therapeutic use (10) 10
phase-ii (10) 10
prednisone - therapeutic use (10) 10
survival (10) 10
vincristine - therapeutic use (10) 10
bleomycin - adverse effects (9) 9
dacarbazine - therapeutic use (9) 9
doxorubicin - adverse effects (9) 9
intergroup trial (9) 9
international prognostic score (9) 9
mopp (9) 9
procarbazine - administration & dosage (9) 9
randomized controlled trials as topic (9) 9
survival rate (9) 9
therapy (9) 9
transplantation (9) 9
abridged index medicus (8) 8
active antiretroviral therapy (8) 8
clinical-trials (8) 8
doxorubicin (8) 8
lymphoma (8) 8
regimen (8) 8
advanced stage (7) 7
antineoplastic agents - therapeutic use (7) 7
bone-marrow-transplantation (7) 7
clinical trials (7) 7
follow-up studies (7) 7
high-dose chemotherapy (7) 7
medicine, general & internal (7) 7
open-label (7) 7
positron-emission tomography (7) 7
radiation therapy (7) 7
salvage therapy (7) 7
toxicity (7) 7
bulky (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 08/2016, Volume 34, Issue 23, pp. 2690 - 2697
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9828, pp. 1791 - 1799
Summary Background The intensity of chemotherapy and need for additional radiotherapy in patients with advanced stage Hodgkin's lymphoma has been unclear. We... 
Internal Medicine | SURVIVAL | ABVD | MEDICINE, GENERAL & INTERNAL | COMBINATIONS | POSITRON-EMISSION-TOMOGRAPHY | DISEASE | PROGNOSTIC SCORE | RISK | STANFORD-V | PROGRESSION | MOPP/ABV HYBRID | Doxorubicin - therapeutic use | Prospective Studies | Hodgkin Disease - pathology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Positron-Emission Tomography | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Treatment Failure | Hodgkin Disease - drug therapy | Adult | Female | Radiotherapy Dosage | Etoposide - adverse effects | Prednisone - adverse effects | Proportional Hazards Models | Etoposide - therapeutic use | Treatment Outcome | Bleomycin - adverse effects | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Vincristine - therapeutic use | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Prednisone - therapeutic use | Chemotherapy | Usage | Care and treatment | PET imaging | Diagnosis | Hodgkin's disease | Cancer | Medical imaging | Meetings | Patient safety | Oncology | Lymphomas | Histology | Radiation therapy | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, ISSN 0732-183X, 08/2019, Volume 37, Issue 23, pp. 1997 - 1997
Nivolumab, an anti-programmed death-1 monoclonal antibody, has demonstrated frequent and durable responses in relapsed/refractory classic Hodgkin lymphoma... 
ABVD | POSITRON-EMISSION-TOMOGRAPHY | PULMONARY TOXICITY | INTERGROUP TRIAL | ONCOLOGY | STANFORD V | BRENTUXIMAB VEDOTIN | EARLY INTERIM | BLEOMYCIN | ADAPTED TREATMENT | CHEMOTHERAPY | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 13, pp. 1348 - 1356
Journal Article
Journal Article
ANNALS OF HEMATOLOGY, ISSN 0939-5555, 07/2019, Volume 98, Issue 7, pp. 1665 - 1674
Hodgkin lymphoma (HL), a disease of mostly young patients, also peaks in the elderly. Despite the profound improvement in the outcome of young patients, in the... 
FINAL ANALYSIS | INTERGROUP TRIAL | BRENTUXIMAB VEDOTIN | RANDOMIZED-TRIAL | STUDY-GROUP GHSG | INTERNATIONAL PROGNOSTIC SCORE | POSITRON-EMISSION-TOMOGRAPHY | OLDER PATIENTS | Interim PET-CT | STANFORD-V | HEMATOLOGY | Elderly | ADAPTED TREATMENT | Hodgkin lymphoma
Journal Article
Radiotherapy and Oncology, ISSN 0167-8140, 12/2018, Volume 129, Issue 3, pp. 507 - 512
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2012, Volume 30, Issue 33, pp. 4117 - 4123
Purpose Although the outcome of patients with HIV-related Hodgkin lymphoma (HIV-HL) has markedly improved since the introduction of combined antiretroviral... 
PROGNOSTIC-FACTORS | ONCOLOGY | INFECTION HD-HIV | ACTIVE ANTIRETROVIRAL THERAPY | DISEASE | RANDOMIZED-TRIAL | STANFORD-V | STEM-CELL TRANSPLANTATION | PATIENTS PTS | IMMUNODEFICIENCY | CHEMOTHERAPY | Procarbazine - administration & dosage | Cyclophosphamide - administration & dosage | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Prospective Studies | Hodgkin Disease - pathology | Humans | Lymphoma, AIDS-Related - pathology | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Young Adult | Hodgkin Disease - radiotherapy | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Lymphoma, AIDS-Related - drug therapy | Dacarbazine - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Etoposide - administration & dosage | Treatment Outcome | Combined Modality Therapy | Bleomycin - administration & dosage | Bleomycin - adverse effects | Remission Induction | Disease-Free Survival | Procarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | HIV Infections - complications | Lymphoma, AIDS-Related - radiotherapy | Vincristine - adverse effects | Aged | Neoplasm Staging | Doxorubicin - adverse effects | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 03/2011, Volume 117, Issue 9, pp. 2596 - 2603
Dose-intensified treatment strategies for Hodgkin lymphoma (HL) have demonstrated improvements in cure but may increase risk for acute and long-term... 
INVOLVED-FIELD | ABVD | POSITRON-EMISSION-TOMOGRAPHY | CLINICAL-TRIALS | DISEASE | STUDY-GROUP GHSG | STANFORD-V | HEMATOLOGY | PEDIATRIC-ONCOLOGY | PROGRESSION | RADIATION-THERAPY | Procarbazine - administration & dosage | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Hodgkin Disease - pathology | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Young Adult | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Time Factors | Antineoplastic Agents - adverse effects | Hodgkin Disease - drug therapy | Vincristine - administration & dosage | Female | Child | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Etoposide - administration & dosage | Etoposide - therapeutic use | Treatment Outcome | Bleomycin - administration & dosage | Bleomycin - adverse effects | Disease-Free Survival | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Vincristine - therapeutic use | Vincristine - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations
Journal Article
Cancer, ISSN 0008-543X, 02/2015, Volume 121, Issue 3, pp. 423 - 431
Journal Article
British Journal of Haematology, ISSN 0007-1048, 11/2015, Volume 171, Issue 4, pp. 530 - 538
Journal Article
BLOOD, ISSN 0006-4971, 12/2016, Volume 128, Issue 22
Conference Proceeding
Medicine, ISSN 0025-7974, 01/2017, Volume 96, Issue 4, pp. e5948 - e5948
Journal Article